Market Research Report
Oncology Drug Discovery Services Market, 2017-2030
|Published by||Roots Analysis||Product code||518832|
|Published||Content info||270 Pages
Delivery time: 1-2 business days
|Oncology Drug Discovery Services Market, 2017-2030|
|Published: June 21, 2017||Content info: 270 Pages||
The early stages of research related to drug discovery, including the identification of a relevant target and a viable lead compound, play a crucial role in the overall success of a drug in preclinical and / or clinical studies. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Moreover, there is always a high risk of failure associated with R&D programs and, given the increasing regulatory stringency, the approval of new drugs has become significantly complex as well. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential to effectively cater to the growing demands associated with drug discovery as well. Contract Research Organizations (CROs), with dedicated teams of experts and innovative solutions across the various stages of the drug discovery and development process, are now located in all major global markets. Employing the services of these CROs offers a number of benefits to drug developers, including access to better technologies, latest R&D tools, cost and time savings and the potential to minimize risks associated with the drug discovery process.
Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. There exists a significantly high unmet need for novel therapeutic options in this domain, translating into a growing demand for drug discovery initiatives. Therefore, CROs have now emerged as important stakeholders in the oncology market. The increasing trend towards outsourcing has triggered the establishment of several strategic collaborations between drug / therapy developers and CROs. In fact, several CROs have acquired other small / mid-sized CROs or collaborated with them for upgrading their own drug discovery capabilities in an effort to provide integrated services to its clients. Opportunities arising from the growth of personalized medicines, the vast unmet need for therapies for orphan indications, and the adoption of novel technology solutions, such as deep learning solutions, cloud-based technology platforms and 3D cell culture systems, are likely to act as some of the primary drivers of growth within this sector.
The “Oncology Drug Discovery Services Market, 2017-2030” report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology. Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease's origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.
With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.
This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process. In addition to other elements, the report features:
In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world. Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market's evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of this study, we invited over 100 stakeholders to participate in a survey, in order to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field.
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
While the focus has been on forecasting the market till 2030. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 presents an executive summary of the insights captured in our research. It offers a high level view on the current state of the oncology drug discovery services market, specific factors impacting its growth and how the opportunity is likely to evolve in the mid-long term.
Chapter 3 provides an introduction to the drug discovery approach. It includes details on the time taken for a drug to traverse from the bench to the market, along with a historical account of the evolution of the drug discovery process. It also provides an in-depth explanation of each of the five steps involved in the drug discovery process, including details on associated methods / technologies / approaches. Further, the chapter features a discussion on the key challenges associated with conducting drug discovery research in-house, highlighting the need for contract services providers and the evident shift towards outsourcing drug discovery related operations in oncology.
Chapter 4 includes a comprehensive overview and analysis of the current market landscape of the oncology drug discovery services market. It features an analysis of drug discovery service providers on the basis of their geographical location, type of drug discovery service provided, depth of service portfolio (discovery / preclinical development / clinical development / commercial manufacturing) and the nature of product (small molecule / biologic).
Chapter 5 provides detailed profiles of some of the oncology drug discovery service providers that offer end-to-end services. Each profile features a brief overview of the company, financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 6 provides detailed profiles of some of the oncology drug discovery service providers that offer target based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 7 provides detailed profiles of some of the oncology drug discovery service providers that offer lead based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 8 provides detailed profiles of some of the oncology drug discovery service providers that specialize in lead optimization. Each profile features presents a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.
Chapter 9 provides a comprehensive market forecast, depicting how the drug discovery services market for oncology is likely to evolve till 2030. We have presented an analysis of the evolving financial opportunity across various regions, such as North America, Europe, China and ROW. Additionally, we have analyzed the market size based on the nature of molecule (biologic, small molecule) and the key steps of drug discovery (target identification, target validation, hit-to-lead, lead identification and lead optimization). It is worth mentioning that our projections are backed by credible data procured from both secondary and primary sources, and a robust forecast approach validated by in-house and external experts.
Chapter 10 provides a detailed benchmark analysis of the companies that provide drug discovery services in the oncology domain. The key parameters considered for this analysis include the depth of the service portfolio, the type of the molecule and the number of services offered by each company within a peer group (based on geography and employee base). The analysis allows the companies to compare their existing capabilities within their peer group and identify opportunities to become more competitive in the industry.
Chapter 11 features an elaborate discussion and analysis on the collaborations and partnerships that have been recently inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. In addition to the aforementioned analysis, the chapter offers an illustrative bubble analysis representing the competitive landscape of players involved in the space, based on their experience, number of drug discovery services offered and the level of activity in terms of collaborations established in the field of oncology research. The key objective of this analysis is to establish a region-wise understanding of contract services offerings and key players involved in the oncology drug discovery market globally.
Chapter 12 highlights important trends that are likely to impact CROs providing drug discovery services and influence their efforts to strengthen their presence in this competitive market. During our research, we identified a number of interesting trends, including focus on personalized medicines, orphan drugs and complex biopharmaceuticals, innovative applications of deep learning, use of 3 D cell culture systems and other novel technologies, which are being developed to reduce the innate complexities associated with drug discovery and optimize the time spent on the overall process. We believe that these trends are likely to significantly influence the industry's evolution over the coming decade.
Chapter 13 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.
Chapter 14 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and key trends that are likely to determine how the market is likely to evolve in the mid- and long terms.
Chapter 15 is a collection of interview transcripts of the discussions held with some of the key players in this industry.
Chapters 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.
The following companies and organizations have been mentioned in the report: